Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923489 | 0.81 | HTR2A (0.42) | HTR2CCA12CA1CA9HSP90AA1 | |
| SCHEMBL23923488 | 0.81 | HTR2A (0.42) | HTR2CCA12CA1CA9HSP90AA1 | |
| SCHEMBL7706827 | 0.80 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL3093088 | 0.78 | HSP90AA1 (0.38) | HTR2CCA12CA1CA9HSP90AA1 | |
| SCHEMBL9988239 | 0.77 | SLC6A4 (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL3182564 | 0.75 | CA12 (0.46) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5508174 | 0.75 | CA12 (0.33) | HTR2CCA12CA1CA9ADRA1A | |
| SCHEMBL2329760 | 0.74 | ACHE (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL4004898 | 0.74 | CYP3A4 (0.47) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5292779 | 0.74 | ACHE (0.45) | CA12CA1CA9NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| CN-115916763-B | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | HTR2C 437/4885DRD2 1908/4885CA12 2835/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | HTR2C 437/4885DRD2 1908/4885CA12 2835/4885 |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | HTR2C 274/4885DRD2 438/4885CA12 3088/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | HTR2C 437/4885DRD2 1908/4885CA12 2835/4885 |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, MAVS | HTR2C 3176/4885DRD2 4053/4885CA12 3710/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | HTR2C 3877/4885DRD2 2060/4885CA12 4101/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HTR2C 958/4885DRD2 268/4885CA12 3689/4885 |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, MAVS | HTR2C 3176/4885DRD2 4053/4885CA12 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.